Brucellosis Vaccines Market Expected to Expand at a Steady 2024-2031 | Merck & Co., Inc., CZ Vaccines, Colorado Serum Company

Market Overview:

Brucellosis vaccines are used for vaccination of cattle, sheep, and goats against brucellosis disease. Brucellosis disease is caused by bacteria of the genus Brucella, which are primarily found in cattle, goats, sheep, and pigs.

Market Dynamics:

The brucellosis vaccines market is driven by increasing prevalence of brucellosis disease globally. According to the World Health Organization (WHO), globally there are over 500,000 new cases annually of brucellosis in humans. The disease causes abortion in animal during the late stages of pregnancy. Moreover, rising government initiatives for disease management through vaccination programs is also expected to augment the market growth over the forecast period. Advancements in vaccine production technologies is further estimated to offer lucrative opportunities in the market.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/5038

Market Drivers

Increased prevalence of Brucellosis globally is driving the demand for effective Brucellosis vaccines

Brucellosis is a bacterial zoonotic disease that is endemic in the Middle East, Mediterranean, parts of Asia, and parts of Latin America. According to WHO, there are over 500,000 new cases reported annually worldwide. The rising incidence of brucellosis infections globally is a major factor boosting the demand and development of efficacious brucellosis vaccines. Countries like China, Mexico and some Middle Eastern nations with high brucellosis burden are focusing on vaccination programs to control the disease which is further fueling the market growth.

Strengthening regulations and guidelines by regulatory bodies regarding vaccination of livestock is propelling the brucellosis vaccine market

Regulatory agencies like European Medicines Agency (EMA) and Centers for Disease Control and Prevention (CDC) have stringent guidelines in place regarding the vaccination and disease management of livestock to prevent zoonotic transmission of brucellosis to humans. For instance, the CDC recommends annual B.abortus strain RB51 vaccination of cattle herds to control the spread of the disease. Similarly, EMA has approved RB51 as the only vaccine available for bovine brucellosis prevention in the EU. Such guidelines mandate vaccination programs which is creating sustained demand for brucellosis vaccines in the market.

Market Restrain

Lack of ideal vaccine with high efficacy and safety profile is impeding the market growth

Currently, the only approved brucellosis vaccine is S19 vaccine for small ruminants and RB51 vaccine for cattle which have certain limitations. S19 vaccine can cause abortion in pregnant animals. RB51 vaccine though safe, provides only partial protection and does not completely prevent infection and colonization in vaccinated animals. This has driven the need for development of more effective second-generation vaccines. However, brucellosis vaccines development is challenging given the intracellular nature of the pathogen and difficulties in correlating immune responses to protection. This roadblock is negatively impacting the overall market expansion.

Market Opportunity

Growing research into novel vaccine delivery platforms and antigen identification is opening new opportunities

Continued research efforts are being focused on improving the vaccine efficacy using advanced vaccine delivery technologies and novel antigen identification. Scientists are investigating the potential of DNA vaccines, recombinant vector vaccines, prime-boost approaches, subunit vaccines and polyvalent vaccines against multi strains which if successful, can transform the brucellosis vaccine landscape. Identification of protective antigens through genome sequencing is also bolstering vaccine design. Particularly, researches involving Venezuelan equine encephalitis viral (VEE) and adenoviral vectors as promising delivery systems hold promise. Successful translation of these R&D initiatives into novel vaccines will present lucrative opportunities in the coming years.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/5038

Market Trends

Rising collaboration between industry and academia for accelerated vaccine development

Given the bottlenecks in brucellosis vaccine advancement, partnerships between private sector companies and research institutes have grown significantly. For example, pharmaceutical company Zoetis is collaborating with different agencies like USDA, CDC and universities to expedite development of advanced bovine and small ruminant brucellosis vaccines.Similarly, Indian based Bharat Biotech has ongoing research programs with Indian Veterinary Research Institute and National Dairy Development Board of India for a thermostable and efficacious brucellosis vaccine. Such collaborations allow seamless transfer of new vaccine candidates from labs into clinical testing and commercialization faster. This trend of leveraging complementary expertise is expected to continue strengthening over the forecast period.

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Brucellosis Vaccines companies, key tactics followed by Leading Key Players:

◘ Merck & Co. Inc.
◘ CZ Vaccines
◘ Colorado Serum Company
◘ Indian Immunologicals Ltd.
◘ Hester Biosciences Limited
◘ Veterinary Technologies Corporation
◘ Jordan Bio-industries Center
◘ Laboratorios Tornel
◘ Fivet Animal Health
◘ VETAL Animal Health Products Inc.

Note: Major Players are sorted in no particular order.

By Type: RB51 Vaccine, S19 Vaccine, B19 Vaccine, Others (45/20 vaccine, SR82 vaccine, etc.)

By Application: Cattle, Sheep, Goat, Others (swine, horses, etc.)

The Study Objectives are:

A comprehensive insight into key players operating in the Brucellosis Vaccines Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Contents:

Market scenario 2023

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the Brucellosis Vaccines market
Chapter 2: Exclusive Summary - the basic information of the Brucellosis Vaccines Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the Brucellosis Vaccines
Chapter 4: Presenting the Brucellosis Vaccines Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2023 - 2030
Chapter 6: Evaluating the leading manufacturers of the Brucellosis Vaccines market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2023-2030)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5038

Key Questions Answered:

What is the market size and CAGR of the Brucellosis Vaccines Market during the forecast period?
How is the growing demand impacting the growth of Brucellosis Vaccines Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC Brucellosis Vaccines Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.